Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501579 | 0.91 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL12501530 | 0.88 | BDKRB1 (0.82) | BDKRB1 | |
| SCHEMBL12501631 | 0.88 | BDKRB1 (0.86) | BDKRB1 | |
| SCHEMBL12501543 | 0.88 | BDKRB1 (0.88) | BDKRB1 | |
| SCHEMBL12501633 | 0.88 | BDKRB1 (0.86) | BDKRB1 | |
| SCHEMBL16242395 | 0.86 | BDKRB1 (0.78) | BDKRB1 | |
| SCHEMBL14575499 | 0.86 | BDKRB1 (0.83) | BDKRB1 | |
| SCHEMBL12501524 | 0.85 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL12501595 | 0.85 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL12501540 | 0.84 | BDKRB1 (1.00) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | claimed |
| EP-2668155-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | claimed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | claimed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | claimed |
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| EP-2668155-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | CYP1A1, AHR, CYP1B1 | BDKRB1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.